Editas Medicine, Inc. (EDIT Quick QuoteEDIT - Free Report) was a big mover last session, as the company saw its shares rise more than 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $29.84 to $35.96 in the past one-month time frame.

The move came after the company has extended its collaboration agreement with Adverum Biotechnologies, Inc. to discover the genome editing medicines for the treatment of nearly five inherited retinal diseases.

The company has not seen any estimate revisions over the past month and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Editas Medicine currently has a Zacks Rank #4 (Sell), while its Earnings ESP is positive.

A better-ranked stock in the Medical - Biomedical and Genetics industry is Bioverativ Inc. , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EDIT going up? Or down? Predict to see what others think: Up or Down

Don’t Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks’ has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>